Table 4: In-hospital outcomes and discharge medication.
| Outcomes | Patients (n = 280) | Male (n = 140) | Female (n = 140) |
| Post procedure pre- discharge events | |||
| Stent thrombosis | 1 (0.4%) | 1 (1.4%) | 0 |
| Heart failure | 10 (3.6%) | 2 (1.4%) | 8 (5.7%) |
| CIN | 10 (3.6%) | 9 (6.4%) | 1 (0.7%) |
| VT/VF | 2 (0.7%) | 1 (0.7%) | 1 (0.7%) |
| Fever | 3 (1.1%) | 0 | 3 (2.1%) |
| MI | 3 (1.1%) | 1 (0.7%) | 2 (1.4%) |
| CVA | 0 | 0 | 0 |
| Death | 1 (0.4%) | 0 | 1 (0.7%) |
| Vascular complications | |||
| Pseudo aneurysm | 2 (0.7%) | 1 (0.7%) | 1 (0.7%) |
| Groin hematoma | 3 (1.1%) | 2 (1.4%) | 1 (0.7%) |
| Retroperitoneal bleeding | 1 (0.4%) | 1 (0.7%) | 0 |
| Medications on discharge | |||
| Aspirin | 279 (99.6%) | 140 (100%) | 139 (99.3%) |
| Plavix | 237 (84.6%) | 122 (87.1%) | 115 (82.1%) |
| Beta blockers | 268 (95.7%) | 129 (92.1%) | 139 (99.3%) |
| ACE | 180 (64.3%) | 96 (68.6%) | 84 (60.4%) |
| ARBS | 99 (35.4%) | 44 (31.4%) | 55 (39.3%) |
| Statins | 279 (99.6%) | 140 (100%) | 139 (99.3%) |
MI: Myocardial Infarction; CVA: Cerebrovascular Accident; ACE: Angiotensin Converting Enzyme Inhibitors; ARBs: Angiotensin Receptors Blockers.